Cargando…

Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout

BACKGROUND: Chikungunya virus (CHIKV) has been responsible for large epidemic outbreaks causing fever, headache, rash and severe arthralgia. So far, no specific treatment or vaccine is available. As nucleic acid amplification can only be used during the viremic phase of the disease, serological test...

Descripción completa

Detalles Bibliográficos
Autores principales: Gläsker, Sabine, Lulla, Aleksei, Lulla, Valeria, Couderc, Therese, Drexler, Jan Felix, Liljeström, Peter, Lecuit, Marc, Drosten, Christian, Merits, Andres, Kümmerer, Beate Mareike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718613/
https://www.ncbi.nlm.nih.gov/pubmed/23855906
http://dx.doi.org/10.1186/1743-422X-10-235
_version_ 1782277789198581760
author Gläsker, Sabine
Lulla, Aleksei
Lulla, Valeria
Couderc, Therese
Drexler, Jan Felix
Liljeström, Peter
Lecuit, Marc
Drosten, Christian
Merits, Andres
Kümmerer, Beate Mareike
author_facet Gläsker, Sabine
Lulla, Aleksei
Lulla, Valeria
Couderc, Therese
Drexler, Jan Felix
Liljeström, Peter
Lecuit, Marc
Drosten, Christian
Merits, Andres
Kümmerer, Beate Mareike
author_sort Gläsker, Sabine
collection PubMed
description BACKGROUND: Chikungunya virus (CHIKV) has been responsible for large epidemic outbreaks causing fever, headache, rash and severe arthralgia. So far, no specific treatment or vaccine is available. As nucleic acid amplification can only be used during the viremic phase of the disease, serological tests like neutralization assays are necessary for CHIKV diagnosis and for determination of the immune status of a patient. Furthermore, neutralization assays represent a useful tool to validate the efficacy of potential vaccines. As CHIKV is a BSL3 agent, neutralization assays with infectious virus need to be performed under BSL3 conditions. Our aim was to develop a neutralization assay based on non-infectious virus replicon particles (VRPs). METHODS: VRPs were produced by cotransfecting baby hamster kidney-21 cells with a CHIKV replicon expressing Gaussia luciferase (Gluc) and two helper RNAs expressing the CHIKV capsid protein or the remaining structural proteins, respectively. The resulting single round infectious particles were used in CHIKV neutralization assays using secreted Gluc as readout. RESULTS: Upon cotransfection of a CHIKV replicon expressing Gluc and the helper RNAs VRPs could be produced efficiently under optimized conditions at 32°C. Infection with VRPs could be measured via Gluc secreted into the supernatant. The successful use of VRPs in CHIKV neutralization assays was demonstrated using a CHIKV neutralizing monoclonal antibody or sera from CHIKV infected patients. Comparison of VRP based neutralization assays in 24- versus 96-well format using different amounts of VRPs revealed that in the 96-well format a high multiplicity of infection is favored, while in the 24-well format reliable results are also obtained using lower infection rates. Comparison of different readout times revealed that evaluation of the neutralization assay is already possible at the same day of infection. CONCLUSIONS: A VRP based CHIKV neutralization assay using Gluc as readout represents a fast and useful method to determine CHIKV neutralizing antibodies without the need of using infectious CHIKV.
format Online
Article
Text
id pubmed-3718613
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37186132013-07-23 Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout Gläsker, Sabine Lulla, Aleksei Lulla, Valeria Couderc, Therese Drexler, Jan Felix Liljeström, Peter Lecuit, Marc Drosten, Christian Merits, Andres Kümmerer, Beate Mareike Virol J Methodology BACKGROUND: Chikungunya virus (CHIKV) has been responsible for large epidemic outbreaks causing fever, headache, rash and severe arthralgia. So far, no specific treatment or vaccine is available. As nucleic acid amplification can only be used during the viremic phase of the disease, serological tests like neutralization assays are necessary for CHIKV diagnosis and for determination of the immune status of a patient. Furthermore, neutralization assays represent a useful tool to validate the efficacy of potential vaccines. As CHIKV is a BSL3 agent, neutralization assays with infectious virus need to be performed under BSL3 conditions. Our aim was to develop a neutralization assay based on non-infectious virus replicon particles (VRPs). METHODS: VRPs were produced by cotransfecting baby hamster kidney-21 cells with a CHIKV replicon expressing Gaussia luciferase (Gluc) and two helper RNAs expressing the CHIKV capsid protein or the remaining structural proteins, respectively. The resulting single round infectious particles were used in CHIKV neutralization assays using secreted Gluc as readout. RESULTS: Upon cotransfection of a CHIKV replicon expressing Gluc and the helper RNAs VRPs could be produced efficiently under optimized conditions at 32°C. Infection with VRPs could be measured via Gluc secreted into the supernatant. The successful use of VRPs in CHIKV neutralization assays was demonstrated using a CHIKV neutralizing monoclonal antibody or sera from CHIKV infected patients. Comparison of VRP based neutralization assays in 24- versus 96-well format using different amounts of VRPs revealed that in the 96-well format a high multiplicity of infection is favored, while in the 24-well format reliable results are also obtained using lower infection rates. Comparison of different readout times revealed that evaluation of the neutralization assay is already possible at the same day of infection. CONCLUSIONS: A VRP based CHIKV neutralization assay using Gluc as readout represents a fast and useful method to determine CHIKV neutralizing antibodies without the need of using infectious CHIKV. BioMed Central 2013-07-15 /pmc/articles/PMC3718613/ /pubmed/23855906 http://dx.doi.org/10.1186/1743-422X-10-235 Text en Copyright ©2013 Gläsker et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology
Gläsker, Sabine
Lulla, Aleksei
Lulla, Valeria
Couderc, Therese
Drexler, Jan Felix
Liljeström, Peter
Lecuit, Marc
Drosten, Christian
Merits, Andres
Kümmerer, Beate Mareike
Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout
title Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout
title_full Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout
title_fullStr Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout
title_full_unstemmed Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout
title_short Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout
title_sort virus replicon particle based chikungunya virus neutralization assay using gaussia luciferase as readout
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718613/
https://www.ncbi.nlm.nih.gov/pubmed/23855906
http://dx.doi.org/10.1186/1743-422X-10-235
work_keys_str_mv AT glaskersabine virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT lullaaleksei virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT lullavaleria virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT couderctherese virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT drexlerjanfelix virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT liljestrompeter virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT lecuitmarc virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT drostenchristian virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT meritsandres virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout
AT kummererbeatemareike virusrepliconparticlebasedchikungunyavirusneutralizationassayusinggaussialuciferaseasreadout